Doxorubicin Market By Application (Ovarian, Multiple Myeloma, Kaposi Sarcoma, Leukemia, Bone Sarcoma, Breast, Endometrial, Gastric, Liver, Kidney, Other Cancers) And Segment Forecasts, 2013 - 2024Report

Doxorubicin Market By Application (Ovarian, Multiple Myeloma, Kaposi Sarcoma, Leukemia, Bone Sarcoma, Breast, Endometrial, Gastric, Liver, Kidney, Other Cancers) And Segment Forecasts, 2013 - 2024

Published: November 2016  |  84 Pages  |  Format: PDF  |  Report ID: GVR-1-68038-288-4

Industry Insights

The global doxorubicin market size was valued at USD 809.6 million in 2015 and is projected to grow at a CAGR of 6.4% over the forecast period. Increasing government intervention to support technological advancement in clinical oncology such as intravenous freetherapy and digital microfluidics for on chip biochemical analysis, is expected to boost the usage rate of the drug during the forecast period.

According to the American Cancer Society (ACS), it was reported that about 38 million people die every year due to non-communicable diseases, with more than 8 million of them dying from tumor malignancy. Furthermore, based on the estimates of the World Health Organization (WHO), the cancer incidence rate could further increase by 50% by 2020. The rising use of the drug to treat AIDS related Kaposi Sarcoma, breast malignancy, multiple myeloma, acute meroblastic leukemia is one of the pivotal factors that is expected to boost the doxorubicin industry value.

North America doxorubicin market by application, 2013 - 2024 (USD Million)

North America doxorubicin market

Application Insights

In 2015, breast cancer application of doxorubicin market held a majority share of over 21%. The rapidly growing number of cases of breast cancer and high preference of doxorubicin over other drugs for the treatment of malignant neoplasm of the breast are some of the factors impelling the industry growth in the coming few years. Based on the analysis of the Breast Cancer Organization, it is anticipated that over 12% of the total women population in the U.S. to develop invasive ductal carcinoma during the course of their lifetime. Increasing the survival rate is one of the indicators for the growing adoption of technologically advanced treatment therapies.

The application of doxorubicin in liver cancer treatment therapies is expected to grow at a lucrative CAGR of 8.0% due to increased prevalence of hepatocellular carcinoma and subsequent growth in the treatment rate. Moreover, doxorubicin is identified as the one of the most effective for the treatment of liver cancer over other drugs which is expected to positively reinforce industry growth.

The growing prevalence of hepatocellular carcinoma and the increasing survival rates are some of the prime factors that indicate the high adoption of advanced medication to treat liver cancer. Some of the most effective systemic chemo liver cancer drugs are 5-fluorouracil, doxorubicin (Adriamycin), and cisplatin. The drugs are used in combination therapy and in monotherapy. The growing usage of the drug in various therapies is one of the crucial factors anticipated to boost their use in treating liver cancer during the forecast period.

Doxorubicin market by region, 2015 & 2024

Doxorubicin market

Regional Insights

In 2015, North America accounted for the maximum revenue share of 48.8 %,which was followed by Europe. The U.S. is the most important sector and captured a majority share of the North American segment. Based on the estimates of the North American Association of Central Cancer Registries, Inc. in 2014, it was stated that over 4,046,058 people were living with various malignant tumor types such as prostate, lung, colon, bladder, breast, and other tumor malignancy.

The growing number of malignancy cases and subsequently increasing usage of the doxorubicin in mono and combination chemotherapies are among few industry impacting factors. Moreover, the increasing number of mergers and acquisitions and partnerships for clinical trials with technologically advanced doxorubicin formulations is one of the crucial factors driving the market in this region. For instance, Aeterna Zentaris announced that it had completed patient recruitment procedures for the ZoptEC phase 3 clinical study with Zoptarelin Doxorubicin for advanced endometrial cancer cases in 2015.

Asia Pacific is expected to emerge as the fastest growing region with a CAGR of 8.3 % over the forecast period.The countries such as India, Japan and China are expected to present growing pharmaceuticals markets.The prevalence of gastric cancer is the third most common type of tumor malignancy, after breast and lung cancer. The incidence rate of stomach malignancy is declining, which further indicates betterment in treatment quality and improvements in drug formulation. These improvements are expected to further drive the anti-cancer drugs market in the coming years.

Competitive Insights

Since the expiry of the patent in 2009 and 2010, a number of companies have entered the doxorubicin market. The market is dominated by players such as Sun Pharmaceutical Industries Ltd., Pfizer, Inc., Cipla, Inc., Cadila Pharmaceuticals, and SRS Pharmaceuticals Pvt. Ltd. The growing number of mergers and acquisitions is one of the key factors to build technical expertise. For instance, Sun Pharmaceuticals Industries Ltd. acquired Ranbaxy Laboratories Ltd in 2015, to expand its presence internationally by reducing the therapeutic gaps in the U.S.

Doxorubicin Report Scope

Attribute

Details

Customization Offer (15% free)*

Additional Cost

Base year

2015

NA

NA

Historic

2013 - 2014

Extended historic data (2012 to 2015)

Free

Forecast

2016 - 2024

Extended Forecast data (2024 – 2026)

Free

Report details

Market size, company share, competitive Landscape, growth factors, trends

Contact us for specific information not available in this report

Quotation to be shared post feasibility

Market representation

USD Million

NA

NA

Geographic coverage

Global & Regional (by country)

Information on up to three additional countries

Free

Company profiles

All major players

Profiles of 10 additional companies

Free

15% free customization - This is equivalent to work done by one research analyst for 5 working days.

Segments Covered in the Report

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2013 to 2024. For the purpose of this study, Grand View Research has segmented the doxorubicin market on the basis ofapplication and region:

  • Application Outlook (Revenue, USD Million, 2013 - 2024)
    • Ovarian Cancer

    • Multiple Myeloma

    • Kaposi Sarcoma

    • Leukemia

    • Bone sarcoma

    • Breast cancer

    • Endometrial cancer

    • Gastric cancer

    • Liver cancer

    • Kidney cancer

    • Other cancer

  • Regional Outlook (Revenue, USD Million, 2013 - 2024)
    • North America

      • U.S

      • Canada

    • Europe

      • Germany

      • UK

    • Asia Pacific

      • China

      • Japan

    • Latin America

      • Brazil

      • Mexico

    • Middle East and Africa

      • South Africa

Key questions answered by the report
Request for Customization

Choose License Type:

Single User - $3,450
Multi User - $6,450
Enterprise User - $8,450

Special Pricing & Discounts

Avail customized purchase options to meet your research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Custom research service

    Custom research service

    Speak to the report author to design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service excellence represented in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • BOA